Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ivabradine Anpharm

regeneron headquarters

Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

- PMLiVE

MSD hangs ‘for sale’ sign on French facility, shedding 207 staff

Job losses will be across manufacturing and R&D divisions

- PMLiVE

TMC rockets on data for twice-yearly cholesterol drug inclisiran

Shares up 14% following announcement

- PMLiVE

Regeneron scores positive data in phase 3 cholesterol trial

Targets severe inherited disorder

- PMLiVE

Amgen gets block on sales of Repatha rival in Germany

Part of ongoing battle with Sanofi and Regeneron

- PMLiVE

England opens new NHS ‘front door’ to health innovators

An upgrade to existing ACC initiative

- PMLiVE

Sanofi gets cardio outcomes claim for Praluent in EU

Data stronger than rival's, could spark a fight back

- PMLiVE

MS and cholesterol drugs picked for new UK rapid uptake push

Accelerated Access Collaborative aims to break down barriers to faster uptake

- PMLiVE

Regeneron’s Dupixent and Praluent falls short

But CEO Len Schleifer says there’s time to fix that

Segmentation, evolved

My research into the evolution of the life science industry reveals broad, sweeping trends, as I wrote about in previous PME articles such as “Selection Pressures” and “Explosive Evolution”. But...

Sanofi reception

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Amgen’s Repatha also struggled to secure reimbursement at its launch price point

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links